Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018144910) METHODS OF PROTECTING AGAINST NEURODEGENERATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/144910 International Application No.: PCT/US2018/016697
Publication Date: 09.08.2018 International Filing Date: 02.02.2018
IPC:
A61P 25/16 (2006.01) ,A61P 25/28 (2006.01) ,C07D 209/18 (2006.01) ,C07D 307/80 (2006.01) ,C07D 333/60 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
02
condensed with one carbocyclic ring
04
Indoles; Hydrogenated indoles
10
with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
18
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
77
ortho- or peri-condensed with carbocyclic rings or ring systems
78
Benzo [b] furans; Hydrogenated benzo [b] furans
79
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
80
Radicals substituted by oxygen atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
333
Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
50
condensed with carbocyclic rings or ring systems
52
Benzo [b] thiophenes; Hydrogenated benzo [b] thiophenes
54
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
60
Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applicants:
BIOVENTURES, LLC [US/US]; 4301 W. Markham St., #831 Little Rock, Arkansas 72205-7199, US
THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US/US]; Department of Veterans Affairs 810 Vermont Avenue NW Washington, District of Columbia 20420, US
Inventors:
REIS, Robert Shmookler; US
CROOKS, Peter; US
AYYADEVARA, Srinivas; US
Agent:
JOHNSON, Charles A.; US
BISSEN, Shirley T.; US
CRAWFORD, Bradley; US
KREPEL, Allison; US
NEALEY, Tara; US
RILEY-VARGAS, Rebecca C.; US
ROBERTS, Brett J.; US
DOTY, Kathryn; US
DEAN, III, Elton F.; US
Priority Data:
62/453,88602.02.2017US
Title (EN) METHODS OF PROTECTING AGAINST NEURODEGENERATION
(FR) PROCÉDÉS DE PROTECTION CONTRE LA NEURODÉGÉNÉRESCENCE
Abstract:
(EN) The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).
(FR) L'invention concerne un procédé de prévention ou de réduction d'agrégats de protéines à l'aide de combrétastatine-A4 (CA4) ou d'un analogue de celle-ci. L'invention concerne également des procédés de réduction du risque, de retardement de l'apparition, de retardement ou de ralentissement de la progression, ou d'inversion des signes ou symptômes d'une maladie neurodégénérative (ou d’une autre maladie évolutive de l'âge) à l'aide d'une combrétastatine-A4 (CA4) ou d'un analogue de celle-ci. La combrétastatine-A4 (CA4) ou un analogue de celle-ci peut se lier à une protéine acide fibrillaire gliale (GFAP). La combrétastatine-A4 (CA4) ou un analogue de celle-ci est décrite par des composés de la formule (I).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)